210 related articles for article (PubMed ID: 27463016)
1. Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Patel S; Hurez V; Nawrocki ST; Goros M; Michalek J; Sarantopoulos J; Curiel T; Mahalingam D
Oncotarget; 2016 Sep; 7(37):59087-59097. PubMed ID: 27463016
[TBL] [Abstract][Full Text] [Related]
2. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Mahalingam D; Mita M; Sarantopoulos J; Wood L; Amaravadi RK; Davis LE; Mita AC; Curiel TJ; Espitia CM; Nawrocki ST; Giles FJ; Carew JS
Autophagy; 2014 Aug; 10(8):1403-14. PubMed ID: 24991835
[TBL] [Abstract][Full Text] [Related]
3. Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Arora SP; Tenner L; Sarantopoulos J; Morris J; Liu Q; Mendez JA; Curiel T; Michalek J; Mahalingam D
Br J Cancer; 2022 Oct; 127(6):1153-1161. PubMed ID: 35739299
[TBL] [Abstract][Full Text] [Related]
4. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Rangwala R; Chang YC; Hu J; Algazy KM; Evans TL; Fecher LA; Schuchter LM; Torigian DA; Panosian JT; Troxel AB; Tan KS; Heitjan DF; DeMichele AM; Vaughn DJ; Redlinger M; Alavi A; Kaiser J; Pontiggia L; Davis LE; O'Dwyer PJ; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1391-402. PubMed ID: 24991838
[TBL] [Abstract][Full Text] [Related]
5. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Karasic TB; O'Hara MH; Loaiza-Bonilla A; Reiss KA; Teitelbaum UR; Borazanci E; De Jesus-Acosta A; Redlinger C; Burrell JA; Laheru DA; Von Hoff DD; Amaravadi RK; Drebin JA; O'Dwyer PJ
JAMA Oncol; 2019 Jul; 5(7):993-998. PubMed ID: 31120501
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Rosenfeld MR; Ye X; Supko JG; Desideri S; Grossman SA; Brem S; Mikkelson T; Wang D; Chang YC; Hu J; McAfee Q; Fisher J; Troxel AB; Piao S; Heitjan DF; Tan KS; Pontiggia L; O'Dwyer PJ; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1359-68. PubMed ID: 24991840
[TBL] [Abstract][Full Text] [Related]
7. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
Bradley D; Rathkopf D; Dunn R; Stadler WM; Liu G; Smith DC; Pili R; Zwiebel J; Scher H; Hussain M
Cancer; 2009 Dec; 115(23):5541-9. PubMed ID: 19711464
[TBL] [Abstract][Full Text] [Related]
8. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort.
Chi KH; Ko HL; Yang KL; Lee CY; Chi MS; Kao SJ
Oncotarget; 2015 Jun; 6(18):16735-45. PubMed ID: 25944689
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.
Fakih MG; Groman A; McMahon J; Wilding G; Muindi JR
Cancer Chemother Pharmacol; 2012 Mar; 69(3):743-51. PubMed ID: 22020318
[TBL] [Abstract][Full Text] [Related]
12. Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.
Gray JE; Saltos A; Tanvetyanon T; Haura EB; Creelan B; Antonia SJ; Shafique M; Zheng H; Dai W; Saller JJ; Chen Z; Tchekmedyian N; Goas K; Thapa R; Boyle TA; Chen DT; Beg AA
Clin Cancer Res; 2019 Nov; 25(22):6623-6632. PubMed ID: 31409616
[TBL] [Abstract][Full Text] [Related]
13. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Malhotra J; Jabbour S; Orlick M; Riedlinger G; Guo Y; White E; Aisner J
Cancer Treat Res Commun; 2019; 21():100158. PubMed ID: 31521049
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
Wilson PM; El-Khoueiry A; Iqbal S; Fazzone W; LaBonte MJ; Groshen S; Yang D; Danenberg KD; Cole S; Kornacki M; Ladner RD; Lenz HJ
Cancer Chemother Pharmacol; 2010 Apr; 65(5):979-88. PubMed ID: 20062993
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
[TBL] [Abstract][Full Text] [Related]
16. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
Carew JS; Medina EC; Esquivel JA; Mahalingam D; Swords R; Kelly K; Zhang H; Huang P; Mita AC; Mita MM; Giles FJ; Nawrocki ST
J Cell Mol Med; 2010 Oct; 14(10):2448-59. PubMed ID: 19583815
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
[TBL] [Abstract][Full Text] [Related]
18. Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer.
Karasic TB; Brown TJ; Schneider C; Teitelbaum UR; Reiss KA; Mitchell TC; Massa RC; O'Hara MH; DiCicco L; Garcia-Marcano L; Amaravadi RK; O'Dwyer PJ
Oncologist; 2022 Sep; 27(9):716-e689. PubMed ID: 35552447
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.
Barnard RA; Wittenburg LA; Amaravadi RK; Gustafson DL; Thorburn A; Thamm DH
Autophagy; 2014 Aug; 10(8):1415-25. PubMed ID: 24991836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
